Invesco Ltd. Cuts Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Invesco Ltd. decreased its holdings in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 95.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 29,906 shares of the biotechnology company’s stock after selling 626,604 shares during the quarter. Invesco Ltd. owned about 0.05% of Aldeyra Therapeutics worth $149,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Catalyst Funds Management Pty Ltd grew its stake in Aldeyra Therapeutics by 2,083.3% in the 4th quarter. Catalyst Funds Management Pty Ltd now owns 13,100 shares of the biotechnology company’s stock worth $65,000 after acquiring an additional 12,500 shares in the last quarter. U.S. Capital Wealth Advisors LLC purchased a new position in shares of Aldeyra Therapeutics during the fourth quarter worth $69,000. SG Americas Securities LLC lifted its holdings in Aldeyra Therapeutics by 14.4% in the fourth quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 2,822 shares during the period. Intech Investment Management LLC raised its position in shares of Aldeyra Therapeutics by 62.7% in the fourth quarter. Intech Investment Management LLC now owns 23,806 shares of the biotechnology company’s stock worth $119,000 after acquiring an additional 9,178 shares during the period. Finally, Boston Financial Mangement LLC purchased a new position in Aldeyra Therapeutics during the fourth quarter worth approximately $141,000. Institutional investors own 59.71% of the company’s stock.

Insider Activity at Aldeyra Therapeutics

In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the business’s stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $1.42, for a total value of $4,828,000.00. Following the transaction, the insider now owns 5,875,851 shares in the company, valued at $8,343,708.42. The trade was a 36.65 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 8.50% of the company’s stock.

Aldeyra Therapeutics Stock Up 3.7 %

ALDX stock opened at $2.81 on Monday. Aldeyra Therapeutics, Inc has a 12 month low of $1.14 and a 12 month high of $7.20. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80. The company has a market cap of $168.31 million, a price-to-earnings ratio of -2.99 and a beta of 0.94. The company has a fifty day moving average price of $4.37 and a 200 day moving average price of $4.96.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its earnings results on Thursday, March 6th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.30). Sell-side analysts expect that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on ALDX shares. BTIG Research dropped their target price on shares of Aldeyra Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a report on Monday, April 7th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Aldeyra Therapeutics in a research report on Friday, April 4th.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.